Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting

• Published in: BMC proceedings Vol. 15; no. Suppl 10; p. 15
• Main Authors: Dawood, Shaheenah, Konstantionva, Maria, Dent, Rebecca, Perazzo, Florencia, Kim, Sung-Bae, Villarreal-Garza, Cynthia, Franco, Sandra, Dai, Ming-Shen, Simon, Sergio
• Format: Journal Article
• Language: English
• Published: England BioMed Central 09.08.2021; BMC
• Subjects: Ablation; Algorithms; Breast cancer; Cancer therapies; Chemotherapy; Confidence intervals; Contraindications; Creatinine; Cyclin-dependent kinase 4/6 inhibitor; Cyclin-dependent kinases; Diarrhea; Endocrine therapy; Growth factors; Health services; Hormone receptor-positive; Human epidermal growth factor receptor 2 negative; Kinases; Leukopenia; Medical prognosis; Meeting Report; Metastatic breast cancer PI3K/mTOR inhibitor; Neutropenia; Optimization; Ovaries; Questions; Receptors; Regional development; Registry; Tumors; Womens health; Metastatic breast cancer PI3K/mTOR inhibitor; Sequence of therapy; Endocrine therapy; Human epidermal growth factor receptor 2 negative; Registry; Hormone receptor-positive; Cyclin-dependent kinase 4/6 inhibitor
• ISSN: 1753-6561; 1753-6561
• DOI: 10.1186/s12919-021-00224-5

The therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR + HER2 - mBC. A panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR + HER2 - mBC. Evidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR + HER2 - mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR + HER2 - mBC. The current article will serve as a comprehensive guide for optimizing the management of HR + HER2 - mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR + HER2 - mBC.